Skip to main content

Advertisement

SpringerLink
Log in

Phase II Trial of Pyrazoloacridine in Patients with Cisplatin-Refractory Germ Cell Tumors

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Thirteen patients with cisplatin-refractory germ cell tumors weretreated on a Phase II trial with pyrazoloacridine.Pyrazoloacridine was given intravenously at 600 mg/m3 everythree weeks. The median nadir leucocyte count was 2.5cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was126,000 cells/m3. None of the thirteen evaluable patientsachieved a major response. Pyrazoloacridine is not efficaciousin the treatment of cisplatin-refractory germ cell tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337: 242–253, 1997

    Google Scholar 

  2. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500–2504, 1998

    Google Scholar 

  3. McCaffrey JA, Mazurridar M, Bajorin DF, Bosi GJ, Vlamis V, Motzer RJ: Ifosfamide-and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559–2563, 1997

    Google Scholar 

  4. Motzer RJ: High dose chemotherapy for germ cell tumors (GCT): Memorial Sloan-Kettering Cancer Center. Bone Marrow Transplant, 18 suppl 1: S53–54, 1996

    Google Scholar 

  5. Adjei, AA: Current status of pyrazoloacridine as an anticancer agent. Invest New Drugs 17: 43–48, 1999

    Google Scholar 

  6. Jackson RC, Sebolt JS, Shillis JL, Leopold WR: The pyrazoloacridines: approaches to the development of a carcinomaselective cytotoxic agent. Cancer Investigation 8: 39–47, 1990

    Google Scholar 

  7. Sebolt JS, Scavone SV, Pinter CD, Hamelechle KL, Von Hoff DD, Jackson RC: Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 47: 4299–4304, 1987

    Google Scholar 

  8. Rowinsky EK, Noe DA, Growchow LB, Sartorious SE, Bowling MK, Chen TL, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic studies of pyrazolacridine, a novel DNA intercalating agent, on single-dosing and multipledosing schedules. J Clin Oncol 13: 1975–1984, 1995

    Google Scholar 

  9. Lo Russo P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L: Phase I clinical trial of pyrazoloacridine NSC 366140 (PD 115934). Clin Cancer Res 1: 1487–1493, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Solid Tumor Oncology, Department of Medicine, Genitourinary Oncology Service, USA and

    Jacqueline Vuky, John McCaffrey, Tania Mariani, Dean F. Bajorin, George J. Bosl & Robert J. Motzer

  2. Department of Medicine, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY, USA

    Jacqueline Vuky, Dean F. Bajorin, George J. Bosl & Robert J. Motzer

  3. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY

    Michelle Ginsberg

Authors
  1. Jacqueline Vuky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John McCaffrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michelle Ginsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tania Mariani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dean F. Bajorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. George J. Bosl
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert J. Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vuky, J., McCaffrey, J., Ginsberg, M. et al. Phase II Trial of Pyrazoloacridine in Patients with Cisplatin-Refractory Germ Cell Tumors. Invest New Drugs 18, 265–267 (2000). https://doi.org/10.1023/A:1006434008357

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006434008357

Search

Navigation